North America dipeptidyl peptidase 4 (DPP-4) inhibitors market is projected to grow at a modest CAGR of 3.4% during the forecast period (2020-2026). The key aspect that drives the growth of the market includes the increased cases of diabetes among the people across the North American region. As per the Centers for Disease Control and Prevention 2020, 34.2 million people in the US have diabetes, which accounts for over 1 in 10 people having diabetes. Dipeptidyl peptidase 4 (DPP-4) inhibitors play a vital role in releasing insulin secretion in the body and control the sugar levels in the body. Besides, the presence of the key players along with the availability of specific branded drugs in the region also supports market growth. For instance, Sitagliptin, Saxagliptin, Linagliptin among others are some of the drugs approved by the US FDA for use in the region. However, numerous side effects associated with the intake of dipeptidyl peptidase 4 (DPP-4) inhibitors in form of drugs and warnings regarding the intake of drugs in combination with others challenge the growth of the market.
North America dipeptidyl peptidase 4 (DPP-4) inhibitors market is segmented on the basis of drug type. Based on the drug type, the market is segmented as Sitagliptin, Vildagliptin, Saxagliptin, Linagliptin, Gemigliptin, Anagliptin, Teneligliptin, and Others. Amongst these drug types of the North America dipeptidyl peptidase 4 (DPP-4) inhibitors, the Sitagliptin, Saxagliptin, and Linagliptin are projected to hold the most lucrative share in the market. Geographically, the North America dipeptidyl peptidase 4 (DPP-4) inhibitors market is segmented into the US and Canada. The US is anticipated to grow considerably over the forecast period.
Further, Boehringer Ingelheim International GmbH, Bristol Myers Squibb Co., Merck & Co., Eli Lily & Co., GlaxoSmithKline Plc, LG Life Sciences Ltd., Novartis AG, Phenomix Corp., and Takeda Pharmaceutical Co. among others are some of the prominent players functioning in the North America dipeptidyl peptidase 4 (DPP-4) inhibitors market. New product launches & developments, partnerships, agreements, and acquisitions are some of the growth strategies adopted by the players in order to sustain in the highly competitive market.
Research Methodology
The market study of the North America dipeptidyl peptidase 4 (DPP-4) inhibitors market is incorporated by extensive primary and secondary research conducted by the research team. Secondary research has been conducted to refine the available data to breakdown the market into various segments, derive total market size, market forecast, and growth rate. Different approaches have been worked on to derive the market value and market growth rate. Our team collects facts and data related to the market from different geography to provide a better regional outlook. In the report, the country-level analysis is provided by analyzing various regional players, regional tax laws and policies, consumer behavior, and macro-economic factors. Numbers extracted from secondary research have been authenticated by conducting proper primary research. It includes tracking down key people from the industry and interviewing them to validate the data. This enables our analyst to derive the closest possible figures without any major deviations in the actual number. Our analysts try to contact as many executives, managers, key opinion leaders, and industry experts. Primary research brings the authenticity of our reports.
Secondary sources include:
The report is intended for pharmaceutical companies, dipeptidyl peptidase 4 (DPP-4) inhibitors manufacturers, research institutes and universities, other related companies, and government organizations for overall market analysis and competitive analysis. The report provides an in-depth analysis of the market size and growth opportunities. The report will serve as a source for 360-degree analysis of the market thoroughly delivering insights into the market for better business decisions.
Market Segmentation:
The Report covers:
1. Report Summary
• Current Industry Analysis and Growth Potential Outlook
• Impact of COVID-19 on the North America Dipeptidyl Peptidase 4 (DPP-4) Inhibitors Industry
• Recovery Scenario of North America Dipeptidyl Peptidase 4 (DPP-4) Inhibitors Industry
1.1. Research Methods and Tools
1.2. Market Breakdown
1.2.1. By Segments
2. Market Overview and Insights
2.1. Scope of the Report
2.2. Analyst Insight & Current Market Trends
2.2.1. Key Findings
2.2.2. Recommendations
2.2.3. Conclusion
3. Competitive Landscape
3.1. Competitive Dashboard
3.2. Key Strategy Analysis
3.3. Key Company Analysis
3.3.1. Overview
3.3.2. Financial Analysis
3.3.3. SWOT Analysis
3.3.4. Recent Developments
4. Market Determinants
4.1. Motivators
4.2. Restraints
4.3. Opportunities
5. Market Segmentation
5.1. North America Dipeptidyl Peptidase 4 (DPP-4) Inhibitors Market by Drug Type
5.1.1. Sitagliptin
5.1.2. Vildagliptin
5.1.3. Saxagliptin
5.1.4. Linagliptin
5.1.5. Gemigliptin
5.1.6. Anagliptin
5.1.7. Teneligliptin
5.1.8. Others
6. Regional Analysis
6.1. US
6.2. Canada
7. Company Profiles
7.1. AstraZeneca Plc
7.2. Boehringer Ingelheim International GmbH
7.3. Bristol Myers Squibb Co.
7.4. Eli Lily & Co.
7.5. GlaxoSmithKline Plc
7.6. LG Life Sciences Ltd.
7.7. Merck & Co.
7.8. Novartis AG
7.9. Pfizer Inc.
7.10. Phenomix Corp.
7.11. Sanofi SA
7.12. Takeda Pharmaceutical Co.
1. NORTH AMERICA DIPEPTIDYL PEPTIDASE 4 (DPP-4) INHIBITORS MARKET RESEARCH AND ANALYSIS BY DRUG TYPE, 2019-2026 ($ MILLION)
2. NORTH AMERICA SITAGLIPTIN MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2019-2026 ($ MILLION)
3. NORTH AMERICA VILDAGLIPTIN MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2019-2026 ($ MILLION)
4. NORTH AMERICA SAXAGLIPTIN MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2019-2026 ($ MILLION)
5. NORTH AMERICA LINAGLIPTIN MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2019-2026 ($ MILLION)
6. NORTH AMERICA GEMIGLIPTIN MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2019-2026 ($ MILLION)
7. NORTH AMERICA ANAGLIPTIN MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2019-2026 ($ MILLION)
8. NORTH AMERICA TENELIGLIPTIN MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2019-2026 ($ MILLION)
9. NORTH AMERICA OTHER DRUG TYPES MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2019-2026 ($ MILLION)
10. NORTH AMERICA DIPEPTIDYL PEPTIDASE 4 (DPP-4) INHIBITORS MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2019-2026 ($ MILLION)
11. US DIPEPTIDYL PEPTIDASE 4 (DPP-4) INHIBITORS MARKET RESEARCH AND ANALYSIS BY DRUG TYPE, 2019-2026 ($ MILLION)
12. CANADA DIPEPTIDYL PEPTIDASE 4 (DPP-4) INHIBITORS MARKET RESEARCH AND ANALYSIS BY DRUG TYPE, 2019-2026 ($ MILLION)
1. NORTH AMERICA DIPEPTIDYL PEPTIDASE 4 (DPP-4) INHIBITORS MARKET SHARE BY DRUG TYPE, 2019 VS 2026 (%)
2. NORTH AMERICA DIPEPTIDYL PEPTIDASE 4 (DPP-4) INHIBITORS MARKET SHARE BY COUNTRY, 2019 VS 2026 (%)
3. US DIPEPTIDYL PEPTIDASE 4 (DPP-4) INHIBITORS MARKET SIZE, 2019-2026 ($ MILLION)
4. CANADA DIPEPTIDYL PEPTIDASE 4 (DPP-4) INHIBITORS MARKET SIZE, 2019-2026 ($ MILLION)